Institutional shares held 93.4 Million
2.24M calls
1.86M puts
Total value of holdings $12.3B
$296M calls
$246M puts
Market Cap $12.4B
94,401,696 Shares Out.
Institutional ownership 98.98%
# of Institutions 448


Latest Institutional Activity in ITCI

Top Purchases

Q1 2025
Pentwater Capital Management LP Shares Held: 5.19M ($684M)
Q1 2025
Davidson Kempner Capital Management LP Shares Held: 3.49M ($460M)
Q1 2025
Ubs Oconnor LLC Shares Held: 3.09M ($408M)
Q1 2025
Farallon Capital Management LLC Shares Held: 3.06M ($403M)
Q1 2025
Citadel Advisors LLC Shares Held: 2.24M ($295M)

Top Sells

Q1 2025
Jpmorgan Chase & CO Shares Held: 760K ($100M)
Q1 2025
Invesco Ltd. Shares Held: 85.1K ($11.2M)
Q1 2025
Avoro Capital Advisors LLC Shares Held: 625K ($82.4M)
Q1 2025
Franklin Resources Inc Shares Held: 256K ($33.7M)
Q1 2025
Pictet Asset Management Holding Sa Shares Held: 41K ($5.41M)

About ITCI

Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder; and in additional neuropsychiatric indications, such as sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease and heart failure; ITI-1284-ODT-SL for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.


Insider Transactions at ITCI

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
899K Shares
From 11 Insiders
Exercise of conversion of derivative security 644K shares
Grant, award, or other acquisition 64.4K shares
Bona fide gift 190K shares
Sell / Disposition
2.21M Shares
From 16 Insiders
Sale (or disposition) back to the issuer 1.45M shares
Payment of exercise price or tax liability 119K shares
Open market or private sale 450K shares
Bona fide gift 190K shares

Track Institutional and Insider Activities on ITCI

Follow Intra-Cellular Therapies, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ITCI shares.

Notify only if

Insider Trading

Get notified when an Intra Cellular Therapies, Inc. insider buys or sells ITCI shares.

Notify only if

News

Receive news related to Intra-Cellular Therapies, Inc.

Track Activities on ITCI